Business Daily Media

Men's Weekly

.

Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel

  • Written by PR Newswire

MELBOURNE, Australia, Nov. 26, 2021 /PRNewswire/ -- Starpharma showed that 100% of evaluable patients with Stage IV prostate cancer have had efficacy responses, utilising one or more standard measures of disease.

DEP® cabazitaxel is a patented, detergent (polysorbate-80[1])-free, nanoparticle version of the conventional cancer drug,...

Refunds to Revenue: AI and loyalty perks help retailers in post-holiday hangover

Australian retailers are turning to artificial intelligence to simplify and automate returns and exchanges, while strengthening loyalty programs a...

Stop reading from the script: Why authenticity is the customer success secret weapon

I’ve been in customer service for years now. As my team has grown, the number one piece of advice I give is to be your...

From Check-in to Touchdown: How AI and smarter systems are transforming the travel industry

Richard Valente, VP of Customer Experience Strategy at TP in Australia, explores how IT-BPM outsourcing is revolutionising the travel sector throu...

Online Christmas shoppers fund climate and biodiversity projects via HealthPost's Click Sphere for Good initiative

Online shoppers with HealthPost’s Flora & Fauna have made 11,000 contributions towards climate and biodiversity projects when ordering parcel ...

US landmark settlement protects SMEs, highlighting flaws in the RBA's proposed blanket card surcharging ban for Australia

Aussie SMEs warn RBA not to ignore global trends, with the current sledgehammer approach threatening business viability and increasing inflation ...

Thryv Australia named Employer of Choice for third consecutive year at Australian Business Awards

Thryv® (NASDAQ: THRY), Australia’s provider of the leading small business marketing and sales software platform, has been awarded the Employer of ...